Hepion Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
HEPA$0.07-17.7%Stored close · as of Jul 8, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Revenues | $— | $— |
| Costs and expenses: | ||
| Research and development | 445,512 | 11,847,348 |
| General and administrative | 3,315,433 | 7,499,230 |
| Asset impairment loss | 402,746 | — |
| Total operating expenses | 4,163,691 | 19,346,578 |
| Loss from operations | (4,163,691) | (19,346,578) |
| Other income (expense): | ||
| Interest expense, net | (24,406) | (1,247,313) |
| Write-off related party note receivable | — | (600,000) |
| Change in fair value of contingent consideration and derivative financial instruments | (4,089,753) | 7,599,263) |
| Inducement expense | — | (2,567,044 |
| Loss before income taxes | (8,277,850) | (16,161,672) |
| Income tax benefit (expense) | — | 2,969,252 |
| Net loss | $(8,277,850) | $(13,192,420) |
| Weighted average common shares outstanding: | ||
| Basic and diluted | 9,409,375 | 122,894 |
| Net loss per common share: (see Note 11) | ||
| Basic and diluted | $(0.88) | $(107.35) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.